The one-drug-many-indications model has steadily grown in popularity since the early 2000s. But Irvine, California–headquartered Tarsus Pharmaceuticals is aiming to bring the model to XDEMVY (lotilaner), an antiparasitic drug that first won FDA-approval in dogs. After licensing lotilaner from Elanco, Tarsus won FDA approval for the drug, under the trade name XDEMVY, for the treatment…
This pill makes blood deadly to mosquitoes and reduced malaria by 26%
A study from the Barcelona Institute for Global Health revealed that ivermectin, usually used to treat river blindness and scabies, can reduce malaria transmission. The BOHEMIA trial is the largest study on ivermectin for malaria, and results revealed that the pill reduced malaria by 26%. As mosquitoes become more resistant to insect repellent and other…
Swissmedic approves first malaria treatment for infants
Swissmedic has approved Novartis’ Coartem Baby as the first malaria medicine for newborns and young infants, the company announced on Tuesday. The treatment was developed in collaboration with the Medicines for Malaria Venture (MMV). Novartis plans to distribute the treatment on a not-for-profit basis to areas where malaria is endemic. This includes the eight African…
GSK to invest £1 billion on infectious disease research
GSK plc (NYSE:GSK) has announced its plans to spend £1 billion over the next ten years on R&D focused on infectious diseases that disproportionately affect lower-income countries. Diseases covered in the research will include malaria, tuberculosis, HIV, neglected tropical diseases (NTDs) and antimicrobial resistance (AMR). The HIV focus will be through ViiV Healthcare, a joint…